Hematopoiesis News 9.15 April 17, 2018 | |
| |
TOP STORYNovel Drug Shows Promise against Acute Myeloid Leukemia Researchers report that an experimental peptide drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describes how the drug works at the molecular level. The findings have led to a Phase I/II clinical trial for patients with advanced AML and advanced myelodysplastic syndrome. [Press release from the Albert Einstein College of Medicine discussing online prepublication in Science Translational Medicine] Press Release 1 | Press Release 2 | Abstract | Video | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)The authors sought to improve both genetic modification and hemoglobin production among human erythroid cells in vitro. To model therapeutic strategies, they transduced human CD34+ cells and peripheral blood mononuclear cells with lentiviral vectors and compared erythropoietin-based erythroid differentiation using fetal-bovine-serum-containing media and serum-free media. [Mol Ther Methods Clin Dev] Full Article Investigators developed a chemically defined, serum and feeder‐free–directed differentiation platform to generate hematopoietic stem‐progenitor cells and resultant adult‐type progeny from induced pluripotent stem cells. [Stem Cells] Full Article Scientists identifies a specific defect in the hematopoiesis of ubiquitin‐green fluorescent protein transgenic mice that compromises the lymphoid‐primed hematopoietic stem cells in the bone marrow and spleen. [Stem Cells] Abstract The authors found that irradiated hematopoietic stem and early progenitor cells, but not lineage-committed progenitors, undergo rapid ATM-dependent apoptosis, which is suppressed upon interaction with bone-marrow stroma cells. [Sci Rep] Full Article A substantial reduction of relapse in myeloproliferative disorders associated with cytomegalovirus reactivation was confirmed by multivariate analysis using time-dependent covariates for high-risk disease, older age, RIC conditioning, ATG, grade II–IV acute, and chronic GVHD. [Bone Marrow Transplant] Abstract Investigators identified that the dual combination of IGF1/R and MEK inhibition using AG1024 and U0126 can sensitize apoptosis-resistant ALL cells to ionising radiation-induced DNA damage irrespective of effect of single pathway inhibition in vitro. [Exp Hematol] Abstract The Physical and Cellular Conditions of the Human Pulmonary Circulation, Enable Thrombopoesis The authors investigated whether there is evidence to support pulmonary platelet production from studies using human conditions. They documented the presence of megakaryocytes (MK) in the human pulmonary circulation and analyzed the role of the vascular microenvironment on MK function. [Exp Hematol] Abstract Microvasculature-Directed Thrombopoiesis in a 3D In Vitro Marrow Microenvironment Researchers report on the development of an in vitro 3D human marrow vascular microenvironment (VME) to study hematopoietic trafficking and the release of blood cells, specifically platelets. They showed that mature megakaryocytes from aspirated marrow as well as megakaryocytes differentiated in culture from CD34+ cells can be embedded in a collagen matrix containing engineered microvessels to create a thrombopoietic VME. [PLoS One] Full Article CLINICAL RESEARCHIn this first-in-human study, scientists aimed to investigate the safety, clinical activity, pharmacokinetics, and pharmacodynamics of tazemetostat, a first-in-class selective inhibitor of enhancer of zeste homolog 2 (EZH2). [Lancet Oncol] Abstract | Press Release | |
| |
REVIEWSNiches for Hematopoietic Stem Cells and Their Progeny Researchers review emerging evidence showing how HSCs and their progeny are regulated by an interdependent network of mesenchymal stromal cells, nerve fibers, the vasculature, and also other hematopoietic cells. [Immunity] Abstract Hematopoietic Stem Cell Transplantation in Its 60s: A Platform for Cellular Therapies Over the last 60 years, more than a million patients received hematopoietic cell transplantation. Having incorporated multiple changes in clinical practices, it remains a complex procedure facing a dual challenge: cure of the underlying disease and prevention of relapse while controlling potentially severe complications. [Sci Transl Med] Abstract Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
SCIENCE NEWSTrovagene, Inc. announced the presentation of data showing that PCM-075 exhibits synergistic activity when combined with FLT3 inhibitors in a human xenograft AML model. [Press release from Trovagene, Inc. discussing research presented at the 2018 American Association for Cancer Research (AACR) Annual Meeting, Chicago] Press Release H3 Biomedicine Inc. announced novel findings from a comprehensive genomic analysis of 6,235 patients across 15 hematologic malignancies. [Press release from H3 Biomedicine Inc. discussing research presented at the 2018 American Association for Cancer Research (AACR) Annual Meeting, Chicago] Press Release | |
| |
INDUSTRY NEWSCancer Researchers Receive More Than $2 Million to Eradicate Common Form of Leukemia Christoph Rader, PhD, associate professor at the Florida campus of The Scripps Research Institute, has been awarded a $2.875 million, five-year grant from the National Cancer Institute to develop unique antibody-drug conjugates engineered to eradicate one of the most common forms of leukemia, chronic lymphocytic leukemia. [The Scripps Research Institute] Press Release City of Hope announced that it is a certified treatment center to administer tisagenlecleucel CAR T cell therapy – the first CAR T cell therapy approved by the FDA – to patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse. [City of Hope] Press Release | |
| |
POLICY NEWSUniversity Declines to Sanction Doctor Who Referred Patient for Deadly Transplant The doctor who referred a cancer patient for the first-ever artificial trachea implant will not face disciplinary action from the University of Iceland in Reykjavik, where he works. Patient Andemariam Beyene died after the implant, a polymer scaffold seeded with his own stem cells, failed. [ScienceInsider] Editorial A Final Dash across the United States: Updates from the 2018 March for Science The March for Science celebrated its anniversary. And although the turnout around the world was significantly smaller than last year, supporters haven’t lost any of their energy. [ScienceInsider] Editorial
| |
EVENTSNEW 37th World Congress of Hematology (ISH) Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position – Stem Cell and Cancer Research (Institute for Research in Biomedicine) Postdoctoral Position – Regulation of Normal and Malignant Hematopoiesis (Karolinska Institutet) Postdoctoral Researchers – Plasticity of Myeloid Cells (BioMed X Innovation Center) Research Group Leader – Plasticity of Myeloid Cells (BioMed X Innovation Center) Postdoctoral Associate – Leukemia (St. Jude Children’s Research Hospital) Tenure Track Faculty Position – Hematopathology (University of Virginia) Postdoctoral Scholar – Clonal Hematopoiesis (Stanford University) Postdoctoral Fellow – Hematopoiesis and Hematopoietic Stem Cell Biology (City of Hope) Postdoctoral Position – Tregs in the Hematopoietic Stem Cell Niche (Columbia University) Postdoctoral Associate – Stem Cell Biology and Cancer Epigenetics (The Jackson Laboratory) Postdoctoral Fellow – Stem Cells, Development & Cancer (Albert Einstein College of Medicine) Postdoctoral Research Fellow – Hematopoiesis (Fred Hutchinson Cancer Research Center) Postdoctoral Positions – Hematopoietic Stem Cells (Memorial Sloan Kettering Cancer Center) Postdoctoral Research Associate – Mechanisms of Leukemia (University of Virginia) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|